United Therapeutics presents preliminary PHINDER study data to develop PH-ILD screening tool at CHEST 2026
UTHR•United Therapeutics plans to present preliminary PHINDER analyses on mortality risk scoring and an update on inhaled treprostinil in its TETON-IPF program at CHEST 2026, Oct. 18-21. The FDA accepted applications for ralinepag in pulmonary arterial hypertension and nebulized treprostinil in idiopathic pulmonary fibrosis.
1. CHEST presentations planned
United Therapeutics said it will present new clinical data at the CHEST 2026 meeting in Phoenix on Oct. 18-21. An oral update will cover how inhaled treprostinil performed in the TETON-IPF program in slowing disease worsening in idiopathic pulmonary fibrosis. Separate PHINDER analyses will address mortality risk scoring in interstitial lung disease and support development of earlier screening approaches for PH-ILD.
2. FDA accepts applications
The FDA accepted a new drug application for ralinepag in pulmonary arterial hypertension and a supplemental new drug application for nebulized treprostinil in idiopathic pulmonary fibrosis.
